Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and combination treatments, that seek to mirror the commercial success of Madrigal’s Rezdiffra.
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play Read More »
